drugset / Trial / NCT01770392

Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin

NCT01770392

Phase 1 Completed 26 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To investigate the effect of the P-gp inducer rifampicin on the pharmacokinetic parameters of nintedanib

Timeline

Start
2013-01
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nintedanib Small molecule 150 mg Oral
Comparator Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.